For patients who cannot tolerate T-DM1 or for whom it is not effective, other treatment options include other HER2-targeted therapies like pertuzumab, lapatinib, and neratinib, as well as various chemotherapy regimens. The choice of treatment depends on several factors, including the patient's prior treatment history and overall health.
